Enanta Pharmaceuticals | ENTA - Selling And Administration Expenses

Stock Price
12.17
Daily Change
0.09 0.75%
Monthly
-15.54%
Yearly
107.68%
Q1 Forecast
12.13

Enanta Pharmaceuticals reported $-1.05 in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Immunic USD -0.24 0.03 Sep/2024
Incyte USD 390.41M 61.33M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
J&J USD 6.75B 831M Dec/2025
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.85B 215M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025